Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm

被引:46
|
作者
Vaisman, Fernanda [1 ,2 ]
Momesso, Denise
Bulzico, Daniel A. [2 ]
Pessoa, Cencita H. C. N. [2 ]
Gonalves da Cruz, Manuel Domingos [3 ]
Dias, Fernando [4 ]
Corbo, Rossana [2 ]
Vaisman, Mario
Michael Tuttle, R. [5 ]
机构
[1] Univ Fed Rio Janeiro, Serv Endocrinol, Rua Rodolpho Paulo Rocco 255, BR-21941913 Rio De Janeiro, RJ, Brazil
[2] Inst Nacl Canc, Centro, Endocrinol Ser, Praca,Cruz Vermelha 23, BR-20230130 Rio De Janeiro, RJ, Brazil
[3] Univ Fed Rio Janeiro, Surg Serv, Rua Rodolpho Paulo Rocco 255, BR-21941913 Rio De Janeiro, RJ, Brazil
[4] Inst Nacl Canc, Centro, Head & Neck Serv, BR-20230130 Rio De Janeiro, RJ, Brazil
[5] Mem Sloan Kettering Canc Ctr, Serv Endocrinol, 1275 York Ave, New York, NY 10065 USA
关键词
D O I
10.1155/2013/398194
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. An individualized risk-based approach to the treatment of thyroid cancer is being extensively discussed in the recent literature. However, controversies about the ideal surgical approach remain an important issue with regard to the impact on prognosis and follow-up strategies. This study was designed to describe clinical outcomes in a cohort of low and intermediate risk thyroid cancer patients treated with thyroid lobectomy. Methods. Retrospective review of 70 patients who underwent lobectomy. Results. After a median follow-up of 11 years, 5 patients (5/70, 7.1%) recurred and 5 had a completion for benign lesions, while 60 patients (86%) continued to be observed without evidence for disease recurrence. Suspicious ultrasound findings were significantly more common in patients that had structural disease recurrence (100% versus 4.3%, p < 0.001). Furthermore, a rising suppressed Tg value over time was also associated with structural disease recurrence (80% versus 21.5%, p = 0.01). After additional therapy, 99% of the patients had no evidence of disease. Conclusions. Properly selected thyroid cancer patients can be treated with lobectomy with excellent clinical outcomes.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid
    Tahara, Makoto
    Schlumberger, Martin
    Elisei, Rossella
    Habra, Mouhammed Amir
    Kiyota, Naomi
    Paschke, Ralf
    Dutcus, Corina E.
    Hihara, Taro
    McGrath, Shannon
    Matijevic, Mark
    Kadowaki, Tadashi
    Funahashi, Yasuhiro
    Sherman, Steven I.
    EUROPEAN JOURNAL OF CANCER, 2017, 75 : 213 - 221
  • [22] In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response
    Vaisman, Fernanda
    Tala, Hernan
    Grewal, Ravinder
    Tuttle, R. Michael
    THYROID, 2011, 21 (12) : 1317 - 1322
  • [23] In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation
    Felipe Zavala, Luis
    Ines Barra, Maria
    Olmos, Roberto
    Tuttle, Michael
    Gonzalez, Hernan
    Droppelmann, Nicolas
    Mosso, Lorena
    Dominguez, Jose M.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2019, 63 (03): : 293 - 299
  • [24] Clinical characteristics and survival analysis of patients with dual primary malignancies containing differentiated thyroid cancer
    Han, Yun
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [25] Clinical Outcomes of Differentiated Thyroid Cancer Patients with Local Recurrence or Distant Metastasis Detected in Old Age
    Han, Ji Min
    Bae, Ji Cheol
    Kim, Hye In
    Kwon, Sam
    Jeon, Min Ji
    Kim, Won Gu
    Kim, Tae Yong
    Shong, Young Kee
    Kim, Won Bae
    ENDOCRINOLOGY AND METABOLISM, 2018, 33 (04) : 459 - 465
  • [26] Clinical Characteristics-Assisted Risk Stratification for Extent of Thyroidectomy in Patients With 1-4 cm Solitary Intrathyroidal Differentiated Thyroid Cancer
    Dong, Fang
    Zhou, Lin
    Wang, Shuntao
    Mao, Jinqian
    Liu, Chunping
    Shi, Wei
    FRONTIERS IN ENDOCRINOLOGY, 2022, 12
  • [27] I-131 therapy of differentiated thyroid tumors less than 1 cm: comparison between two different therapeutic regimens.
    Storto, G
    Klain, M
    Bracigliano, A
    Paone, G
    Capacchione, D
    Albanese, C
    Pace, L
    Soricelli, A
    Salvatore, M
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S291 - S291
  • [28] Thyroid Lobectomy for Low-Risk 1–4 CM Papillary Thyroid Cancer is not Associated with Increased Recurrence Rates in the Dutch Population with a Restricted Diagnostic Work-Up
    J. F. Lin
    P. M. Rodriguez Schaap
    M. J. H. Metman
    E. J. M. Nieveen van Dijkum
    C. Dickhoff
    T. P. Links
    S. Kruijff
    A. F. Engelsman
    World Journal of Surgery, 2023, 47 : 1211 - 1218
  • [29] Thyroid cancer in children: A multicenter international study highlighting clinical features and surgical outcomes of primary and secondary tumors
    Martucci, Cristina
    Crocoli, Alessandro
    De Pasquale, Maria Debora
    Spinelli, Claudio
    Strambi, Silvia
    Brazzarola, Paolo
    Morelli, Eleonora
    Cassiani, Jessica
    Mancera, Juliana
    Luengas, Juan Pablo
    Lobos, Pablo
    Liberto, Daniel
    Astori, Estefania
    Sarnacki, Sabine
    Couloigner, Vincent
    Simon, Francois
    Lambert, Cassandre
    Abib, Simone de Campos Vieira
    Cervantes, Onivaldo
    Caran, Eliana
    Delgado Lindman, Diana
    Jones, Matthew O.
    Shukla, Rajeev
    Losty, Paul D.
    Inserra, Alessandro
    FRONTIERS IN PEDIATRICS, 2022, 10
  • [30] Thyroid Cancer in Children: A Multicenter International Study Highlighting Clinical Features and Surgical Outcomes of Primary and Secondary Tumors
    Martucci, C.
    Crocoli, A.
    De Pasquale, M. D.
    Spinelli, C.
    Strambi, S.
    Brazzarola, P.
    Morelli, E.
    Cassiani, J.
    Mancera, J.
    Luengas, J.
    Lobos, P.
    Liberto, D.
    Astori, E.
    Sarnacki, S.
    Couloigner, V.
    Simon, F.
    Cervantes, O.
    Caran, E.
    Lindeman, D.
    Losty, P.
    Jones, M.
    Shukla, R.
    Inserra, A.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S17 - S17